Production and Evaluation of a Recombinant Chimeric Vaccine against Clostridium botulinum Neurotoxin Types C and D

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Gil, Luciana A F ^a   da Cunha, Carlos Eduardo P ^a   Moreira, Gustavo M S G ^a   Salvarani, Felipe M ^b   Assis, Ronnie A ^b   Lobato, Francisco Carlos F ^b   Mendonça, Marcelo ^a   Dellagostin, Odir A ^a   Conceição, Fabricio R ^a  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; ANTITOXIN; BOTULINUM TOXIN; BOTULINUM TOXIN C; BOTULINUM TOXIN D; CHIMERIC PROTEIN; ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI HEAT LABILE ENTEROTOXIN B SUBUNIT; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; BOTULISM; CATTLE; CLOSTRIDIUM BOTULINUM; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GUINEA PIG; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION CONTROL; MOUSE; NONHUMAN; SEROTYPE; TOXIN STRUCTURE; VACCINATION;

ALUMINUM HYDROXIDE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; BACTERIAL TOXINS; BASE SEQUENCE; BLOTTING, WESTERN; BOTULINUM TOXINS; BOTULISM; CATTLE; CLOSTRIDIUM BOTULINUM TYPE C; CLOSTRIDIUM BOTULINUM TYPE D; DRUG EVALUATION; ENTEROTOXINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI PROTEINS; FEMALE; GUINEA PIGS; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84881161671     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069692     Document Type: Article

References (52)

1. Smith LA, (2009) Botulism and vaccines for its prevention. Vaccine 27: D33-D39. doi:10.1016/j.vaccine.2009.08.059. PubMed: 19837283.
2. Simpson LL, (2004) Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 44: 167-193. doi:10.1146/annurev.pharmtox.44.101802.121554. PubMed: 14744243.
3. Lobato CFF, Salvarani FM, Silva ROS, Souza AM, Lima CGRD, et al. (2008) Botulism in ruminants being fed with poultry litter. Cienc Rural 38: 1176-1178. doi:10.1590/S0103-84782008000400046.
4. Maboni F, Monego F, Matiuzzi da Costa M, Dutra I, Castagna de Vargas Palmira A, (2010) Ocorrência De Botulismo Em Bovinos Confinados No Rio Grande Do Sul. Cienc Animal Bras 11: 962-965.
5. Costa GMD, Salvador SC, Pereira MN, (2008) Botulismo em bovinos leiteiros no Sul de Minas Gerais, Brasil. Cienc Rural 38: 2068-2071. doi:10.1590/S0103-84782008000700045.
6. Döbereiner J, Tokarnia CH, Langenegger J, Dutra IS, (1992) Epizootic botulism of cattle in Brazil. Dtsch Tierarztl Wochenschr 99: 188-190. PubMed: 1638962.
7. Dutra IS, Dobereiner J, Rosa IV, Souza LAA, Nonato M, (2001) Surtos de botulismo em bovinos no Brasil associados à ingestão de água contaminada. Pesqui Vet Bras 21: 43-48. doi:10.1590/S0100-736X2001000200002.
8. Dutra IS, Döbereiner J, Souza AM, (2005) Botulismo em bovinos de corte e leite alimentados com cama de frango. Pesqui Vet Bras 25: 115-119.
9. Payne JH, Hogg RA, Otter A, Roest HI, Livesey CT, (2011) Emergence of suspected type D botulism in ruminants in England and Wales (2001 to 2009), associated with exposure to broiler litter. Vet Rec 168: 640. doi:10.1136/vr.d1846. PubMed: 21652657.
10. Böhnel H, Neufeld B, Gessler F, (2005) Botulinum neurotoxin type B in milk from a cow affected by visceral botulism. Vet J 169: 124-125. doi:10.1016/j.tvjl.2004.01.006. PubMed: 15683776.
11. Livesey CT, Sharpe RT, Hogg RA, (2004) Recent association of cattle botulism with poultry litter. Vet Rec 154: 734-735. PubMed: 15214523.
12. Steinman A, Galon N, Arazi A, Bar-Giora Y, Shpigel NY, (2007) Cattle immune response to botulinum type D toxoid: results of a vaccination study. Vaccine 25: 7636-7640. doi:10.1016/j.vaccine.2007.08.051. PubMed: 17913314.
13. Lee J-C, Hwang H-J, Sakaguchi Y, Yamamoto Y, Arimitsu H, et al. (2007) C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Microbiol Immunol 51: 445-455. PubMed: 17446685.
14. Hakami RM, Ruthel G, Stahl AM, Bavari S, (2010) Gaining ground: assays for therapeutics against botulinum neurotoxin. Trends Microbiol 18: 164-172. doi:10.1016/j.tim.2010.02.001. PubMed: 20202845.
15. Turton K, Chaddock JA, Acharya KR, (2002) Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 27: 552-558. doi:10.1016/S0968-0004(02)02177-1. PubMed: 12417130.
16. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, et al. (2007) Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 75: 3043-3054. doi:10.1128/IAI.01893-06. PubMed: 17371853.
17. Byrne MP, Smith LA, (2000) Development of vaccines for prevention of botulism. Biochimie 82: 955-966. doi:10.1016/S0300-9084(00)01173-1. PubMed: 11086225.
18. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, et al. (2008) Subunit vaccine against the seven serotypes of botulism. Infect Immun 76: 1314-1318. doi:10.1128/IAI.01025-07. PubMed: 18070903.
19. Dux MP, Huang J, Barent R, Inan M, Swanson ST, et al. (2011) Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(H(c))] expressed in Pichia pastoris. Protein Expr Purif 75: 177-185. doi:10.1016/j.pep.2010.09.016. PubMed: 20933089.
20. Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, et al. (2011) Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine 29: 7688-7695. doi:10.1016/j.vaccine.2011.07.134. PubMed: 21839134.
21. Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, et al. (2007) Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 25: 4273-4282. doi:10.1016/j.vaccine.2007.02.081. PubMed: 17395341.
22. Conceição FR, Moreira AN, Dellagostin OA, (2006) A recombinant chimera composed of R1 repeat region of Mycoplasma hyopneumoniae P97 adhesin with Escherichia coli heat-labile enterotoxin B subunit elicits immune response in mice. Vaccine 24: 5734-5743. doi:10.1016/j.vaccine.2006.04.036. PubMed: 16730864.
23. Grassmann AA, Félix SR, dos Santos CX, Amaral MG, Seixas Neto ACP, et al. (2012) Protection against lethal leptospirosis after vaccination with LipL32 coupled or coadministered with the B subunit of Escherichia coli heat-labile enterotoxin. Clin Vaccine Immunol 19: 740-745. doi:10.1128/CVI.05720-11. PubMed: 22379066.
24. Berzofsky JA, Ahlers JD, Belyakov IM, (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1: 209-219. doi:10.1038/35105075. PubMed: 11905830.
25. Fischer G, Conceiçao FR, Leite FPL, Moraes CM, Ferreira LN, et al. (2010) Recombinant Escherichia coli heat-labile enterotoxin B subunit humoral adjuvant effect depends on dose and administration route. World J Microbiol Biotechnol 26: 489-495. doi:10.1007/s11274-009-0195-z.
26. da Hora VP, Conceição FR, Dellagostin OA, Doolan DL, (2011) Non-toxic derivatives of LT as potent adjuvants. Vaccine 29: 1538-1544. doi:10.1016/j.vaccine.2010.11.091. PubMed: 21163247.
27. Sambrook J, Russel DW, (2001) Molecular cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
28. Brasil, (2002) Ministério da Agricultura. Instrução normativa n. 23. Diário Oficial da União.
29. Mansour AA, Mousavi SL, Rasooli I, Nazarian S, Amani J, et al. (2010) Cloning, high level expression and immunogenicity of 1163-1256 residues of C-terminal heavy chain of C. botulinum neurotoxin type E. Biol J Int Assoc Biol Stand 38: 260-264.
30. Yari K, Fatemi SS-A, Tavallaei M, (2012) High level expression of recombinant BoNT/A-Hc by high cell density cultivation of Escherichia coli. Bioprocess Biosyst Eng 35: 407-414. doi:10.1007/s00449-011-0579-y. PubMed: 21833619.
31. Woodward LA, Arimitsu H, Hirst R, Oguma K, (2003) Expression of HC subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 71: 2941-2944. doi:10.1128/IAI.71.5.2941-2944.2003. PubMed: 12704175.
32. Arimitsu H, Lee J-C, Sakaguchi Y, Hayakawa Y, Hayashi M, et al. (2004) Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum Type C and D neurotoxins. Clin Diagn Lab Immunol 11: 496-502. PubMed: 15138174.
33. Yari K, Fatemi SS-A, Tavallaei M, Tavallaei M, (2010) Optimization of the BoNT/A-Hc expression in recombinant Escherichia coli using the Taguchi statistical method. Biotechnol And Appl Biochemistry 56: 35-42. doi:10.1042/BA20090315. PubMed: 20412050.
34. Bie C-Q, Yang D-H, Liang X-J, Tang S-H, (2010) Construction of non-covalent single-chain Fv dimers for hepatocellular carcinoma and their biological functions. World J Hepatol 2: 185-191. PubMed: 21160994.
35. Menezes MA, Aires KA, Ozaki CY, Ruiz RM, Pereira MC, et al. (2011) Cloning approach and functional analysis of anti-intimin single-chain variable fragment (scFv). BMC Res Notes 4: 30. doi:10.1186/1756-0500-4-30. PubMed: 21288327.
36. Sakamoto S, Pongkitwitoon B, Nakamura S, Sasaki-Tabata K, Tanizaki Y, et al. (2011) Construction, expression, and characterization of a single-chain variable fragment antibody against 2,4-dichlorophenoxyacetic acid in the hemolymph of silkworm larvae. Appl Biochem Biotechnol 164: 715-728. doi:10.1007/s12010-011-9168-4. PubMed: 21279468.
37. Skrlj N, Vranac T, Popović M, CurinŠerbec V, Dolinar M, (2011) Specific binding of the pathogenic prion isoform: development and characterization of a humanized single-chain variable antibody fragment. PloS one 6: e15783.
38. Sakamoto S, Tanizaki Y, Pongkitwitoon B, Tanaka H, Morimoto S, (2011) A chimera of green fluorescent protein with single chain variable fragment antibody against ginsenosides for fluorescence-linked immunosorbent assay. Protein Expr Purif 77: 124-130. doi:10.1016/j.pep.2011.01.010. PubMed: 21277981.
39. Dang Z, Feng J, Yagi K, Sugimoto C, Li W, et al. (2012) Mucosal Adjuvanticity of Fibronectin-Binding Peptide (FBP) Fused with Echinococcus multilocularis Tetraspanin 3: Systemic and Local Antibody Responses. PLOS Neglected Trop Dis 6: e1842. doi:10.1371/journal.pntd.0001842. PubMed: 23029596.
40. Yu Y-Z, Li N, Zhu H-Q, Wang R-L, Du Y, et al. (2009) The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 27: 2816-2822. doi:10.1016/j.vaccine.2009.02.091. PubMed: 19428892.
41. Gelzleichter TR, Myers MA, Menton RG, Niemuth NA, Matthews MC, et al. (1999) Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol JAT 19 (Suppl 1):: S35-S38. doi:10.1002/(SICI)1099-1263(199912)19:1+. PubMed: 10594898.
42. Shone C, Agostini H, Clancy J, Gu M, Yang H-H, et al. (2009) Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun 77: 2795-2801. doi:10.1128/IAI.01252-08. PubMed: 19398544.
43. Takeda M, Kasai H, Torii Y, Mukamoto M, Kohda T, et al. (2006) Protective effect of botulinum C/D mosaic toxoid against avian botulism. J Vet Med Sci, 68: 325-30/ The Japanese Society of Veterinary Science 68: 325-330. PubMed: 16679722.
44. Liljeqvist S, Ståhl S, Andréoni C, Binz H, Uhlén M, et al. (1997) Fusions to the cholera toxin B subunit: influence on pentamerization and GM1 binding. J Immunol Methods 210: 125-135. doi:10.1016/S0022-1759(97)00170-1. PubMed: 9520296.
45. Arakawa T, Yu J, Chong DKX, Hough J, Engen PC, et al. (1998) A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 16: 934-938. doi:10.1038/nbt1098-934. PubMed: 9788349.
46. Zeng J, Deng G, Wang J, Zhou J, Liu X, et al. (2011) Potential protective immunogenicity of recombinant Clostridium perfringens α-β2-β1 fusion toxin in mice, sows and cows. Vaccine 29: 5459-5466. doi:10.1016/j.vaccine.2011.05.059. PubMed: 21641956.
47. Freytag LC, Clements JD, (2005) Mucosal adjuvants. Vaccine 23: 1804-1813. doi:10.1016/j.vaccine.2004.11.010. PubMed: 15734046.
48. Hunter RL, (2002) Overview of vaccine adjuvants: present and future. Vaccine 20 (Suppl 3):: S7-S12. doi:10.1016/S0264-410X(02)00164-0. PubMed: 12184369.
49. Hubbell JA, Thomas SN, Swartz MA, (2009) Materials engineering for immunomodulation. Nature 462: 449-460. doi:10.1038/nature08604. PubMed: 19940915.
50. Petrovska L, Lopes L, Simmons CP, Pizza M, Dougan G, et al. (2003) Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 21: 1445-1454. doi:10.1016/S0264-410X(02)00696-5. PubMed: 12615441.
51. Sanchez J, Holmgren J, (2011) Cholera toxin- a foe & a friend. Indian J Med Res 133: 153-163. PubMed: 21415489.
52. George-chandy A, Eriksson K, Lebens M, Nordström I, Schön E, et al. (2001) Cholera Toxin B Subunit as a Carrier Molecule Promotes Antigen Presentation and Increases CD40 and CD86 Expression on Antigen-Presenting Cells. Infect Immun 69: 5716-5725. doi:10.1128/IAI.69.9.5716-5725.2001. PubMed: 11500448.